Evidence map›Paper›PMID 35804888›Full record

ArticleCancers2022

Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study.

Vikas Soni, Manish Adhikari, Li Lin, Jonathan H Sherman, Michael Keidar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vikas SoniMicro-Propulsion and Nanotechnology Laboratory, Department of Mechanical and Aerospace Engineering, The George Washington University, Science and Engineering Hall, 800 22nd Street, NW, Washington, DC 20052, USA.ORCID 0000-0002-0729-4641
Manish AdhikariMicro-Propulsion and Nanotechnology Laboratory, Department of Mechanical and Aerospace Engineering, The George Washington University, Science and Engineering Hall, 800 22nd Street, NW, Washington, DC 20052, USA.ORCID 0000-0002-5633-1533
Li LinMicro-Propulsion and Nanotechnology Laboratory, Department of Mechanical and Aerospace Engineering, The George Washington University, Science and Engineering Hall, 800 22nd Street, NW, Washington, DC 20052, USA.
Jonathan H ShermanDepartment of Neurosurgery, Rockefeller Neuroscience Institute, West Virginia University, 880 N Tennessee Avenue, Suite 104, Martinsburg, WV 25401, USA.
Michael KeidarMicro-Propulsion and Nanotechnology Laboratory, Department of Mechanical and Aerospace Engineering, The George Washington University, Science and Engineering Hall, 800 22nd Street, NW, Washington, DC 20052, USA.ORCID 0000-0003-0869-4310
George Washington University · USWest Virginia University · US

Funding

National Science Foundation 1747760
6 · The paper itself

Abstract

Cold atmospheric plasma (CAP) has been used for the treatment of various cancers. The anti-cancer properties of CAP are mainly due to the reactive species generated from it. Here, we analyze the efficacy of CAP in combination with temozolomide (TMZ) in two different human glioblastoma cell lines, T98G and A172, in vitro using various conditions. We also establish an optimized dose of the co-treatment to study potential sensitization in TMZ-resistant cells. The removal of cell culture media after CAP treatment did not affect the sensitivity of CAP to cancer cells. However, keeping the CAP-treated media for a shorter time helped in the slight proliferation of T98G cells, while keeping the same media for longer durations resulted in a decrease in its survivability. This could be a potential reason for the sensitization of the cells in combination treatment. Co-treatment effectively increased the lactate dehydrogenase (LDH) activity, indicating cytotoxicity. Furthermore, apoptosis and caspase-3 activity also significantly increased in both cell lines, implying the anticancer nature of the combination. The microscopic analysis of the cells post-treatment indicated nuclear fragmentation, and caspase activity demonstrated apoptosis. Therefore, a combination treatment of CAP and TMZ may be a potent therapeutic modality to treat glioblastoma. This could also indicate that a pre-treatment with CAP causes the cells to be more sensitive to chemotherapy treatment.

Indexed as

A172apoptosiscancercancer therapycaspase-3cell deathcold atmospheric plasma (CAP)glioblastomain vitrolactate dehydrogenase (LDH)microscopyreactive oxygen speciessensitizationT98Gtemozolomide

Identifiers

PMID35804888
PMCPMC9264842
OpenAlexW4283453474

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.